Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration

Journal of Clinical Investigation

Volumn 106, Issue 4, 2000, Pages 511-521

  Dias, Sergio ^a   Hattori, Koichi ^a,b   Zhu, Zhenping ^c   Heissig, Beate ^b   Choy, Margaret ^a   Lane, William ^a   Wu, Yan ^c   Chadburn, Amy ^a   Hyjek, Elizabeth ^a   Gill, Muhammad ^a   Hicklin, Daniel J ^c   Witte, Larry ^c   Moore, M A S ^b   Rafii, Shahin ^a,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Division of Hematology/Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; VASCULOTROPIN RECEPTOR;

ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CANCER TRANSPLANTATION; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0033861874     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI8978     Document Type: Article

References (28)

1. Ziegler, B.L., et al. 1999. KDR receptor: a key marker defining hematopoietic stem cells. Science. 285:1553-1558.
2. Fiedler, W., et al. 1997. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 89:1870-1875.
3. Bellamy, W.T., Richter, L., Frutiger, Y., and Grogan, T.M. 1999. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 59:728-733.
4. Katoh, O., Tauchi, H., Kawaishi, K., Kimura, A., and Satow, Y. 1995. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 55:5687-5692.
5. Klagsbrun, M., and D'Amore, P.A. 1996. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 7:259-270.
6. Ortega, N., et al. 1997. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype. Am. J. Pathol. 151:1215-1224.
7. Shalaby, F., et al. 1995. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376:62-66.
8. Fong, G.H., Rossant, J., Gertsenstein, M., and Breitman, M.L. 1995. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 376:66-70.
9. Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S., and Fusenig, N.E. 1997. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. 3:1222-1227.
10. Prewett, M., et al. 1999. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59:5209-5218.
11. Millauer, B., Shawver, L.K., Plate, K.H., Risau, W., and Ullrich, A. 1994. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 367:576-579.
12. Strawn, L.M., et al. 1996. Flk-1 as a target for tumor growth inhibition. Cancer Res. 56:3540-3545.
13. Zhu, Z., et al. 1998. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res. 58:3209-3214.
14. Lu, D., et al. 2000. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies. J. Biol. Chem. 275:14321-14330.
15. Leber, T.M., and Balkwill, F.R. 1997. Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal. Biochem. 249:24-28.
16. Hamada, T., et al. 1998. Transendothelial migration of megakaryocytes in response to stromal cell derived factor 1 (SDF-1) enhances platelet formation. J. Exp. Med. 188:539-548.
17. Fusetti, L., et al. 2000. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe immunocompromised mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res. 60:2527-2534.
18. Clutterbuck, R.D., et al. 1998. Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. Br. J. Haematol. 102:522-527.
19. Terpstra, W., et al. 1995. Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice. Leukemia. 9:1573-1577.
20. Machado, E.A., et al. 1984. Proliferation and differentiation of human myeloid leukemic cells in immunodeficient mice: electron microscopy and cytochemistry. Blood. 63:1015-1022.
21. Salven, P., Manpaa, H., Orpana, A., Alitalo, K., and Joensuu, H. 1997. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin. Cancer Res. 3:647-651.
22. Obermair, A., et al. 1998. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. Br. J. Cancer. 77:1870-1874.
23. Kranz, A., Mattfeldt, T., and Waltenberger, J. 1999. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int. J. Cancer. 84:293-298.
24. Abu-Jawdeh, G.M., et al. 1996. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab. Invest. 74:1105-1115.
25. Ferrer, F.A., et al. 1999. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology. 54:567-572.
26. Folkman, J. 1997. Angiogenesis and angiogenesis inhibition: an overview. EXS. 79:1-8.
27. Perez-Atayde, A.R., et al. 1997. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 150:815-821.
28. Fielder, W., et al. 1997. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia. 11:1234-1237.